Pro ad report: All the data on journal spending in 1H 2016

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

MMM Staff

October 11, 2016

2:40 pm

Professional advertising spending behind brands like Gilead Sciences’ hepatitis-C pill Harvoni and Allergan’s IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. But cancer drugs once again were the hottest category. Check out the latest data on professional ad spending here or read a deep drive into Merck’s journal spending on Keytruda, its immuno-oncology therapy, in the first half of 2016.

Source: Kantar Media

Source: Kantar Media

Source: Kantar Media

Source: Kantar Media

From the October 02, 2016 Issue of MM+M - Medical Marketing and Media

From Our Partners

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.